Literature DB >> 15388439

Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood.

Yoichi Inoue1, Masato Homma, Yasushi Matsuzaki, Minoru Shibata, Takuya Matsumura, Takayoshi Ito, Keiji Mitamura, Naomi Tanaka, Yukinao Kohda.   

Abstract

Ribavirin-induced hemolytic anemia is one cause for cessation of combination therapy with alpha interferon 2b and ribavirin for hepatitis C infection. Determining cellular ribavirin levels in blood, including the levels of its phosphorylated metabolites, might be useful for predicting ribavirin-induced anemia, because the metabolites accumulate in erythrocytes. We simplified an assay method developed previously to make it suitable for routine monitoring of cellular ribavirin. Whole blood diluted with a sixfold volume of ice-cold distilled water was subjected to acid phosphatase digestion to convert phosphorylated ribavirin metabolites to free ribavirin. The resulting mixture, spiked with an internal standard, was treated by phenyl boronic acid column extraction, followed by reverse-phase high-performance liquid chromatography analysis. The calibration curve for ribavirin levels in whole blood was linear at concentrations of 5.3 to 1,024 microM (r(2) = 0.9999). Validation coefficients of variation for intra- and interday assays were 2.9 to 5.8% and 4.3 to 8.3%, respectively. We tested this method by monitoring blood ribavirin concentrations in two hepatitis C patients receiving alpha interferon 2b-plus-ribavirin combination therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388439      PMCID: PMC521879          DOI: 10.1128/AAC.48.10.3813-3816.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Side effects of therapy of hepatitis C and their management.

Authors:  Michael W Fried
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia.

Authors:  Masato Homma; Yasushi Matsuzaki; Yoichi Inoue; Minoru Shibata; Keiji Mitamura; Naomi Tanaka; Yukinao Kohda
Journal:  Clin Gastroenterol Hepatol       Date:  2004-04       Impact factor: 11.382

3.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen.

Authors:  S Crotty; D Maag; J J Arnold; W Zhong; J Y Lau; Z Hong; R Andino; C E Cameron
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

4.  Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters.

Authors:  S M Jarvis; J A Thorn; P Glue
Journal:  Br J Pharmacol       Date:  1998-04       Impact factor: 8.739

5.  High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay.

Authors:  G G Granich; D J Krogstad; J D Connor; K L Desrochers; C Sherwood
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

6.  Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.

Authors:  L De Franceschi; G Fattovich; F Turrini; K Ayi; C Brugnara; F Manzato; F Noventa; A M Stanzial; P Solero; R Corrocher
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

7.  Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus.

Authors:  J J Lertora; A B Rege; J T Lacour; N Ferencz; W J George; R B VanDyke; K C Agrawal; N E Hyslop
Journal:  Clin Pharmacol Ther       Date:  1991-10       Impact factor: 6.875

8.  Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

Authors:  O Reichard; G Norkrans; A Frydén; J H Braconier; A Sönnerborg; O Weiland
Journal:  Lancet       Date:  1998-01-10       Impact factor: 79.321

9.  Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

Authors:  J F Jen; P Glue; S Gupta; D Zambas; G Hajian
Journal:  Ther Drug Monit       Date:  2000-10       Impact factor: 3.681

10.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

Authors:  Mitchell L Shiffman; Adrian M Di Bisceglie; Karen L Lindsay; Chihiro Morishima; Elizabeth C Wright; Gregory T Everson; Anna S Lok; Timothy R Morgan; Herbert L Bonkovsky; William M Lee; Jules L Dienstag; Marc G Ghany; Zachary D Goodman; James E Everhart
Journal:  Gastroenterology       Date:  2004-04       Impact factor: 22.682

View more
  2 in total

1.  Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.

Authors:  Francois-Ludovic Sauvage; Francoise Stanke-Labesque; Marie-Claude Gagnieu; Jean-Francois Jourdil; Gerard Babany; Pierre Marquet
Journal:  Ther Drug Monit       Date:  2009-06       Impact factor: 3.681

2.  An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis C.

Authors:  Sheng-Hung Chen; Cheng-Yuan Peng; Hsueh-Chou Lai; Wen-Pang Su; Chia-Hsin Lin; Yu-Fen Li; Po-Heng Chuang; Ching-Hsiang Chen
Journal:  Hepat Mon       Date:  2015-03-20       Impact factor: 0.660

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.